申请人:INIMMUNE CORP
公开号:WO2019157509A1
公开(公告)日:2019-08-15
Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
具有以异构糖为核心的Toll样受体(TLR)配体在水性配方中稳定,并且在治疗、预防或减少由TLRs介导的疾病或病况方面具有用处,如癌症、传染病、过敏、自身免疫疾病、败血症和缺血再灌注。